TLDR
- Nanexa stock jumped more than 120% in early Friday trading after news of a licensing deal with Novo Nordisk.
- The agreement is worth up to €1.17 billion ($1.33 billion) and covers long-acting injectable drugs.
- Novo Nordisk gets exclusive rights to Nanexa’s PharmaShell technology for up to five development programs.
- The deal targets obesity, type 2 diabetes, and other cardiometabolic diseases.
- Nanexa will earn low single-digit royalties on global sales from any resulting products.
Nanexa stock more than doubled in value on Friday morning. The Swedish drug-delivery company saw its shares rocket over 120% after announcing a major licensing deal with Novo Nordisk.
The agreement was revealed after U.S. market hours closed on Thursday. It’s worth up to €1.17 billion, or roughly $1.33 billion.
Nanexa shares hit their highest level in more than five years following the news. Trading volume spiked as investors rushed to react to the announcement.
The deal centers on Nanexa’s PharmaShell technology. It’s a drug delivery platform that uses an ultra-thin coating on individual drug particles.
That coating helps control how a drug releases into the body over time. Think of it as a slow-release mechanism built at a microscopic level.
What the Deal Covers
Novo Nordisk now holds exclusive worldwide rights to use PharmaShell in up to five development programs. The focus is on obesity, type 2 diabetes, and other cardiometabolic conditions.
The two companies are aiming to create long-acting injectable formulations. The goal is to allow monthly or quarterly dosing instead of the weekly injections common in this space today.
Fewer injections could mean easier treatment routines for patients managing chronic conditions. That’s the pitch behind the partnership.
Novo Nordisk will lead all global development and commercialization efforts tied to the deal. Nanexa’s role centers on the underlying technology itself.
Payment Breakdown
Of the total €1.17 billion, €615 million comes from upfront payments plus development and regulatory milestones. The rest is linked to future sales milestones.
Nanexa will also collect royalties on global net sales for any products that come out of the collaboration. Those royalties sit in the low single-digit percentage range.
It’s a structure common in pharma licensing deals. The smaller partner gets guaranteed cash upfront, then a smaller ongoing cut if the drugs actually reach the market and sell.
Nanexa described the partnership as combining its atomic layer deposition drug delivery platform with Novo Nordisk’s experience in obesity and diabetes treatments. The company shared that description in its press release announcing the deal.
As of 0723 GMT Friday, Nanexa shares were trading up around 122%. Novo Nordisk stock, meanwhile, was up a modest 1% following the announcement
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Be the first to comment